Haleon (LON:HLN) Price Target Raised to GBX 335

Haleon (LON:HLN) had its price objective increased by JPMorgan Chase & Co. from GBX 315 to GBX 335 in a research note published on Wednesday, MarketBeat Ratings reports. JPMorgan Chase & Co. currently has an underweight rating on the stock.

A number of other equities analysts have also recently issued reports on the company. Royal Bank Of Canada restated a “sector perform” rating and set a GBX 370 price objective on shares of Haleon in a report on Friday, October 31st. The Goldman Sachs Group reiterated a “buy” rating and set a GBX 440 target price on shares of Haleon in a research report on Wednesday, September 10th. Berenberg Bank boosted their target price on shares of Haleon from GBX 507 to GBX 517 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 440 price target on shares of Haleon in a research note on Monday, November 3rd. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of GBX 420.40.

Haleon Stock Down 0.3%

Shares of LON:HLN opened at GBX 369.07 on Wednesday. The firm has a market capitalization of £32.87 billion, a PE ratio of 22.10, a price-to-earnings-growth ratio of 1.49 and a beta of 0.19. The business has a 50 day simple moving average of GBX 351.31 and a two-hundred day simple moving average of GBX 366.94. Haleon has a 1 year low of GBX 325.10 and a 1 year high of GBX 419.50. The company has a debt-to-equity ratio of 53.36, a current ratio of 0.84 and a quick ratio of 0.93.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other.